Fictions of Dementia; Parkinson’s Psychosis; CBD as Schedule V

The “comforting fictions” of dementia care are the focus of a New Yorker article.

Pimavanserin (Nuplazid) did not carry a significant different mortality risk than quetiapine (Seroquel) or the combination of both medications among patients with Parkinson’s disease psychosis, UC San Diego researchers reported. (Neurology)

The DEA placed FDA-approved cannabidiol products containing no more than 0.1% THC — including GW Pharma’s Epidiolex, which recently was approved for rare forms of childhood epilepsy — in its least restrictive category, Schedule V.

Low-dose amitriptyline (Elavil) may be an effective treatment for chronic low back pain, a small randomized clinical trial found. (JAMA Internal Medicine)

HHS released Facing Addiction in America: The Surgeon General’s Spotlight on Opioids, a 40-page report to educate readers about opioid misuse, abuse, overdose, and treatment in one document.

The global burden of Parkinson’s disease more

... read more at: https://www.medpagetoday.com/neurology/generalneurology/75439

by

Fictions of Dementia; Parkinson’s Psychosis; CBD as Schedule V

The “comforting fictions” of dementia care are the focus of a New Yorker article.

Pimavanserin (Nuplazid) did not carry a significant different mortality risk than quetiapine (Seroquel) or the combination of both medications among patients with Parkinson’s disease psychosis, UC San Diego researchers reported. (Neurology)

The DEA placed FDA-approved cannabidiol products containing no more than 0.1% THC — including GW Pharma’s Epidiolex, which recently was approved for rare forms of childhood epilepsy — in its least restrictive category, Schedule V.

Low-dose amitriptyline (Elavil) may be an effective treatment for chronic low back pain, a small randomized clinical trial found. (JAMA Internal Medicine)

HHS released Facing Addiction in America: The Surgeon General’s Spotlight on Opioids, a 40-page report to educate readers about opioid misuse, abuse, overdose, and treatment in one document.

The global burden of Parkinson’s disease more

... read more at: https://www.medpagetoday.com/neurology/generalneurology/75439

by